Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02179359 · ClinicalTrials.gov registry record · NA
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT02179359: Clinical Trial NA study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT02179359 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02179359, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
Interventions
- DRUG Reduced Toxicity Ablative Regimen
- DRUG Reduced Intensity Preparative Regimen
- DRUG Myeloablative Preparative Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-09-02 |
| Est. Completion | 2024-11-21 |
| Phase | NA |
Why NCT02179359 stopped before completion
NCT02179359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Reduced Toxicity Ablative Regimen is the first listed.
NCT02179359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02179359 about?
NCT02179359 is a clinical study titled "Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies". This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
What is the current status of trial NCT02179359?
This trial is currently terminated. It is a NA study. The enrollment target is 38 participants. The study started on 2014-09-02. Estimated completion is 2024-11-21.
What interventions are being tested in trial NCT02179359?
The interventions under investigation include: Reduced Toxicity Ablative Regimen (DRUG), Reduced Intensity Preparative Regimen (DRUG), Myeloablative Preparative Regimen (DRUG).
Who is sponsoring clinical trial NCT02179359?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02179359's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI